Protyon provides an analysis service examines the effect of mutations in specific proteins targeted for treatment in lung cancer.
Protyon has raised $655K in total funding. The most recent round was Pre-Seed. The last funding was announced in May 2023.
Protyon's investors include LUMO labs, NV NOM.
Protyon is headquartered in Groningen, The Netherlands.
Protyon provides an analysis service examines the effect of mutations in specific proteins targeted for treatment in lung cancer.
Protyon is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Protyon — Funding & Investors." VCBacked, May 11, 2023, https://www.vcbacked.co/company/protyon. Accessed August 13, 2026.
VCBacked. (2023). Protyon — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/protyon
{{cite web |title=Protyon — Funding & Investors |url=https://www.vcbacked.co/company/protyon |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated